Y
Yuanzhuo Gao
Researcher at Chinese Academy of Sciences
Publications - 6
Citations - 107
Yuanzhuo Gao is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Colitis & Immune system. The author has an hindex of 4, co-authored 6 publications receiving 51 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Heng Li,Chen Fan,Chunlan Feng,Yanwei Wu,Huimin Lu,Pei-Lan He,Xiaoqian Yang,Fenghua Zhu,Qing Qi,Yuanzhuo Gao,Jianping Zuo,Wei Tang +11 more
TL;DR: This study was designed to explore whether PDE4 inhibition by apremilast exerts protective effects in dextran sulfate sodium‐induced murine UC.
Journal ArticleDOI
Heme protects intestinal mucosal barrier in DSS-induced colitis through regulating macrophage polarization in both HO-1-dependent and HO-1-independent way
Yanwei Wu,Bing Wu,Zongwang Zhang,Huimin Lu,Chen Fan,Qing Qi,Yuanzhuo Gao,Heng Li,Chunlan Feng,Jianping Zuo,Wei Tang +10 more
TL;DR: Results showed that the modification of colon tissue microenvironment with heme supplementation plays a protective role in DSS‐induced colitis mice through regulating the macrophage polarization in both HO‐1‐dependent and HO‐ 1‐independent way, indicating a new choice to therapeutically modulate the macophage function and prevent IBD.
Journal ArticleDOI
Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders.
Zhicheng Xie,Bing Wu,Yingqiang Liu,Yingqiang Liu,W.J. Ren,Linjiang Tong,Caigui Xiang,Wei Aihuan,Yuanzhuo Gao,Limin Zeng,Hua Xie,Wei Tang,Youhong Hu +12 more
TL;DR: A detailed structure-activity-relationship study led to the discovery of a new series of compounds with nanomolar IC50 values against CSF-1R without the inhibition of fibroblast growth factor receptors, and one of the most promising hits, compound 29, exhibited strong in vivo anti-inflammatory efficacy alongside favorable drug characteristics.
Journal ArticleDOI
RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-immuno crosstalk.
Huimin Lu,Heng Li,Chen Fan,Qing Qi,Yu-xi Yan,Yanwei Wu,Chunlan Feng,Bing Wu,Yuanzhuo Gao,Jianping Zuo,Wei Tang +10 more
TL;DR: It is demonstrated that RIPK1 inhibitor could ameliorate the intestinal barrier injury by reducing tight junctions' disruption and accompanying oxidative stress and exerts suppressive function in intestinal inflammatory response.
Journal ArticleDOI
Triptolide analog LLDT-8 ameliorates psoriasis-like dermatitis in BALB/c mice via suppressing the IL-36α signaling pathway.
Qing Qi,Qian Li,Qian Li,Hongwen Zhu,Huimin Lu,Xiaoqian Yang,Yanwei Wu,Chunlan Feng,Chen Fan,Heng Li,Bing Wu,Yuanzhuo Gao,Zongwang Zhang,Zongwang Zhang,Hu Zhou,Jianping Zuo,Wei Tang +16 more
TL;DR: Li et al. as mentioned in this paper investigated the effects and underlying mechanisms of (5R)-5-hydroxytriptolide (LLDT-8) on a murine psoriasis-like dermatitis model and related cell lines.